Cyclin E1 protein overexpression sensitizes ovarian cancer cells to ZN-c3, a novel, selective and oral bioavailable inhibitor of Wee1

被引：4
|
作者：
Ma, Jianhui
Liu, Wen
Chung, Heekyung
Izadi, Hooman
DeJong, Petrus
Harismendy, Olivier
Li, Jia
Donate, Fernando
Samatar, Ahmed
Lackner, Mark
Escoubet, Laure
Bunker, Kevin
Kim, Daehwan
Jameson, Nathan
Ozmen, Tugba Yildiran
Jeong, Kangjin
Zhang, Dong
Pan, Wen-An
Mills, Gordon
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2153
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2153
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 dose-escalation trial in patients with advanced solid tumors.
    Tolcher, Anthony
    Mamdani, Hirva
    Chalasani, Pavani
    Meric-Bernstam, Funda
    Gazdoiu, Mihaela
    Makris, Lukas
    Pultar, Philippe
    Voliotis, Dimitris
    CANCER RESEARCH, 2021, 81 (13)
  • [12] BH3 mimetics synergize with the Wee1 inhibitor ZN-c3 by activating caspases which induce DNA damage and degrade key proteins
    Izadi, Hooman
    Ibrahim, Noah
    Hoang, Tiffany
    Ma, Jianhui
    de Jong, Petrus R.
    Pinchman, Joseph
    Bunker, Kevin D.
    Samatar, Ahmed A.
    Donate, Fernando
    CANCER RESEARCH, 2022, 82 (12)
  • [13] Discovery of ZN-c3, a potent Wee-1 inhibitor with a differentiated pharmacologic and kinase selectivity profile.
    Li, Jiali
    Boren, Brant
    Huang, Peter Q.
    Bunker, Kevin D.
    Donate, Fernando
    Samatar, Ahmed A.
    CANCER RESEARCH, 2021, 81 (13)
  • [14] A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML)
    Smith, Catherine Choy
    Vachhani, Pankit
    Garcia-Manero, Guillermo
    Grieselhuber, Nicole Renee
    Murthy, Guru Subramanian Guru
    Bhatia, Astha
    Arora, Jatinder
    Izadi, Hooman
    Fiorino, Anthony
    Rampal, Raajit
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [15] A novel, potent and selective inhibitor of Wee1 with robust antitumor activity in various cancer xenograph models
    Gavory, Gerald
    O'Dowd, Colin
    Burkamp, Frank
    Rountree, Shane
    Rozycka, Ewelina
    Boyd, Caroline
    Gorges, Beronia
    Burton, Stephanie
    Wilkinson, Andy
    Shepherd, Steven
    Janssen, Dominic
    McFarland, Mary
    Rountree, Shane
    Harrison, Tim
    CANCER RESEARCH, 2016, 76
  • [16] The WEE1 inhibitor AZD-1775 has synergic activity with trabectedin or lurbinectedin in ovarian cancer cells
    Uboldi, Sarah
    Carrassa, Laura
    Frapolli, Roberta
    Ubezio, Paolo
    Erba, Eugenio
    D'Incalci, Maurizio
    CANCER RESEARCH, 2016, 76
  • [17] Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis
    G Chen
    B Zhang
    H Xu
    Y Sun
    Y Shi
    Y Luo
    H Jia
    F Wang
    Oncogene, 2017, 36 : 6863 - 6872
  • [18] Combination of the BCL-2 inhibitor ZN-d5 with the WEE1 inhibitor ZN-c3 shows additive or synergistic anti-tumor activity in acute myeloid leukemia (AML) models
    Izadi, Hooman
    Hoang, Tiffany
    Ibrahim, Noah
    Pinchman, Joseph
    Boren, Brant C.
    Ma, Jianhui
    de Jong, Petrus R.
    Li, Jiali
    Bunker, Kevin D.
    Samatar, Ahmed A.
    Donate, Fernando
    CANCER RESEARCH, 2022, 82 (12)
  • [19] Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis
    Chen, G.
    Zhang, B.
    Xu, H.
    Sun, Y.
    Shi, Y.
    Luo, Y.
    Jia, H.
    Wang, F.
    ONCOGENE, 2017, 36 (50) : 6863 - 6872
  • [20] ZN-c3, a potent and selective Wee-1 inhibitor demonstrates anti-tumor activities in combination with other targeted therapies and overcomes PARP inhibitor resistance
    Li, Jiali
    Ma, Jianhui
    de Jong, Petrus R.
    Izadi, Hooman
    Hoang, Tiffany
    Ibrahim, Noah
    Boren, Brant
    Hegde, Sayee Hegde
    Donate, Fernando
    Samatar, Ahmed A.
    CANCER RESEARCH, 2022, 82 (12)
12345